- Home
- CMPO vs PHVS Comparison
CMPO vs PHVS Comparison
Compare CMPO & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPO
- PHVS
- Stock Information
- Founded
- CMPO 2000
- PHVS 2015
- Country
- CMPO United States
- PHVS Switzerland
- Employees
- CMPO N/A
- PHVS N/A
- Industry
- CMPO Finance: Consumer Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- CMPO Finance
- PHVS Health Care
- Exchange
- CMPO Nasdaq
- PHVS Nasdaq
- Market Cap
- CMPO 1.2B
- PHVS 980.9M
- IPO Year
- CMPO N/A
- PHVS 2021
- Fundamental
- Price
- CMPO $14.60
- PHVS $23.00
- Analyst Decision
- CMPO Strong Buy
- PHVS Buy
- Analyst Count
- CMPO 8
- PHVS 6
- Target Price
- CMPO $16.19
- PHVS $37.17
- AVG Volume (30 Days)
- CMPO 790.9K
- PHVS 62.3K
- Earning Date
- CMPO 08-06-2025
- PHVS 08-13-2025
- Dividend Yield
- CMPO N/A
- PHVS N/A
- EPS Growth
- CMPO N/A
- PHVS N/A
- EPS
- CMPO N/A
- PHVS N/A
- Revenue
- CMPO N/A
- PHVS N/A
- Revenue This Year
- CMPO $7.79
- PHVS N/A
- Revenue Next Year
- CMPO $8.61
- PHVS N/A
- P/E Ratio
- CMPO N/A
- PHVS N/A
- Revenue Growth
- CMPO N/A
- PHVS N/A
- 52 Week Low
- CMPO $6.08
- PHVS $11.51
- 52 Week High
- CMPO $15.10
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- CMPO 57.36
- PHVS 67.34
- Support Level
- CMPO $14.18
- PHVS $17.63
- Resistance Level
- CMPO $14.58
- PHVS $26.33
- Average True Range (ATR)
- CMPO 0.39
- PHVS 1.74
- MACD
- CMPO -0.07
- PHVS 0.60
- Stochastic Oscillator
- CMPO 46.99
- PHVS 65.35
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.